Vivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update
HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the first quarter ended March 31, 2022.
- Vivos has also trained over 1,500 dentists in the use of The Vivos Method and Vivos related value-added services, compared to just over 1,200 as of the first quarter of 2021.
- In January 2022, Vivos announced an 18X increase in home sleep tests performed by Vivos-trained dentists in the fourth quarter of 2021 versus the fourth quarter of 2020.
- Also in January 2022, Vivos filed a U.S. patent application related to certain new and enhanced clinical methods and protocols developed within Vivos proprietary Vivos Method treatment for OSA.
- The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.